Economic information and modeling reportBudget impact model
Epidemiology and eligible population inputs
5 evidence topics · 5 sources
Company estimate of the annual U.S. population with mCRPC previously treated with abiraterone
Abiraterone share of new androgen receptor pathway inhibitor prescriptions
Modeled annual U.S. incidence of mCRPC
“The model estimated the prevalence of prostate cancer as 2,219,280 in the US in 2009 and 3,072,480 in 2020, and incidence of mCRPC as 36,100 and 42,970, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The nmCRPC clinical state contributed heavily to the mCRPC states (86%), while the incidence flow from the non-castrate state to mCRPC was <15%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Androgen receptor pathway inhibitor use before mCRPC diagnosis and as first-line mCRPC treatment
“Before mCRPC diagnosis, most patients (73.9% [3963/5361]) had not received treatment intensification; 867 (16.2%) had received prior ARPi only; 448 (8.4%), prior taxane only; and 83 (1.5%), both prior ARPi and taxane.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The use of ARPi-only treatment before mCRPC diagnosis rose from 10.3% in 2018 to 34.8% in 2023.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Over the study course, the majority (76.8%) of patients received an ARPi as 1L treatment for mCRPC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment by line of therapy among Medicare beneficiaries with mCRPC
“22% received no life-prolonging therapy after mCRPC, 78% received ≥1 line of therapy (LOT), 42% underwent ≥2 LOTs, and 20% had ≥3 LOTs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common therapies were abiraterone (36%), enzalutamide (28%), and docetaxel (16%) for 1 L; enzalutamide (33%), abiraterone (28%), and docetaxel (15%) for 2 L; and docetaxel (24%), enzalutamide (19%), and abiraterone (17%) for 3 L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For 37% of all mCRPC patients, NHTs were the only life-prolonging therapy they received.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For those initiating 1 L treatment with NHTs, only 28% received subsequent treatment with a different class of therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote